Bordetella pertussis is the causative agent of whooping cough, a particularly severe disease of young children characterized by repeated bouts of severe paroxysmal coughing. Until recently this disease was controlled through vaccination. However, increasing concern about side effects associated with immunization with whole-cell preparations of B. pertussis has led to decreased vaccine acceptability. This in turn has been accompanied by an increase in the incidence of whooping cough (22) . It is therefore imperative that an effective, nonreactogenic vaccine of higher acceptability be developed. Virulence-associated gene products that have been suggested for incorporation into a purified-component, acellular vaccine include pertussis toxin, filamentous hemagglutinin, serotype-specific fimbriae, adenylate cyclase, and major outer membrane proteins (21, 22) . Expression of the genes encoding all of these antigens is positively controlled by the virulence regulatory determinant, bvg (6, 11, 29) . Purification of such proteins from B. pertussis is hampered by poor bacterial growth rates, low yields, antigenic variation, and the presence of other reactogenic contaminants. To avoid these problems, attempts have been made to obtain expression of recombinant antigens in Escherichia coli by using strong transcriptional and translational signals. The five genes encoding pertussis toxin have been expressed in E. coli under the control of the lambda PL promoter (3) . The serotype 2 fimbrial subunit gene has also been expressed from the lambda PL and PR promoters (28) . However, in neither case did the recombinant products assemble to form products, pertussis holotoxin and serotype 2 fimbriae, respectively, that were immunologically identical to the native products. On the other hand, pertussis holotoxin is produced in recombinant Bordetella parapertussis and Bordetella bronchiseptica and is expressed from its native promoter (13) . Nontoxic mutant pertussis toxin has also been ex-* Corresponding author. pressed in B. pertussis (10, 19) . In (16) . Transformation was carried out by the method of Hanahan (7) . Agarose gel electrophoresis was as previously described (27) . DNA (4) . Samples were heated at 80°C for 10 min and electrophoresed as described for DNA sequence reactions.
Transfer of broad-host-range plasmids to Bordetella spp. E. coli strains containing both pRK600 and pDSK519 derivatives were grown overnight in nutrient broth containing antibiotics selective for both plasmids. A 1.0-ml sample of each culture was pelleted by centrifugation at 3,000 x g for 15 min and resuspended in 1.0 ml of 0.9% NaCl. The suspension was used to overlay 3-day-old plate cultures of Bordetella spp., and the plates were incubated for 4 h at 37°C. The mating mixtures selecting for Bordetella spp. recombinants with cephalexin and kanamycin were then plated out.
Protein purification and analysis. Wild-type serotype 2 fimbriae from B. pertussis Tohama were dissociated from the bacterial cell surface with 4 M urea at 60°C, partially purified by the method of Mooi et al. (17) , and further purified by using CL-6B gel filtration chromatography following the protocol of Irons et al. (8) . Methionylated mature recombinant protein was purified from inclusion bodies essentially by the method of Nagai and Th0gersen (18) Immunological techniques. Mouse antiserum was prepared as previously described (28) . Rabbit antiserum was prepared by emulsifying 200 ,ug of protein at a ratio of 1:1 with Freund incomplete adjuvant in a final volume of 1.0 ml. Groups of two three-month-old chinchilla bastard rabbits were injected subcutaneously and intramuscularly on day 1, day 14, and day 28. After 35 days, the rabbits were sacrificed and the blood was collected and allowed to clot for 3 h at room temperature. Erythrocytes were pelleted at 9,000 x g, and the serum was collected, pooled, and stored at -20°C until use. Western immunoblotting was carried out essentially by the method of Burnette (2) . Antibodies that react with the serotype 2 fimbrial subunit were raised in rabbits (see Fig.  3A ) or mice (see Fig. 3B and C) (antisera were chosen on the basis of least nonspecific reactivity). The detection system used was Bio-Rad horseradish peroxidase-conjugated goat anti-rabbit or goat anti-mouse immunoglobulin G with 4-chloro-1-naphthol as a substrate. Serotype-specific agglutination and the preparation of serotype 2-specific antiserum cross-adsorbed against B. pertussis H36, B. parapertussis MIS180, and B. bronchiseptica 5376 were carried out as previously described (20) . For enzyme-linked immunosorbent assay (ELISA) and immunoelectron microscopy, crossadsorbed rabbit antibodies were purified by using a protein A-Sepharose CL-4B column (Pharmacia) by applying the recommended procedure and adjusting the protein concentration to 400 jig of immunoglobulin G per ml. ELISA was performed by adjusting protein concentrations to 10 ,ug/ml in phosphate-buffered saline (pH 7.4; PBS) and allowing 100-,ul triplicate samples and a PBS blank to adsorb to Nunc Maxisorp Immunomodule 96-well plates overnight at 4°C.
Protein samples were removed, and wells were blocked with 200 RI1 of 0.3% gelatin in PBS for 2 h at 37°C. Plates were washed three times with PBS, and a 50-,ul sample of 1:200 PBS-diluted serotype 2-specific rabbit antibodies was added to each well. After 15 min at room temperature, the plates were again washed and a 100-,ul sample of Bio-Rad horseradish peroxidase-conjugated goat anti-rabbit antibody diluted 1:1,000 in PBS was added to each well and incubated for 1 h at room temperature. The plates were again washed and then developed by the addition of 200 p.1 per well of activated substrate solution (consisting of 10 ml of 0.1 M citric acid, 10 ml of 0.2 M Na2HPO4, 20 ml of distilled H20, 40 pl of 30% H202, and 40 mg of o-phenyldiamine dihydrochloride). After an appropriate time, the reaction was stopped by the addition of 50 ,ul of 0.25 M H2SO4 and the A490 was determined with a Bio-Rad model 3550 microplate reader. The standard deviation was calculated for each triplicate sample.
Immunoelectron microscopy. Bacterial strains grown on plates were gently suspended in 250 R1. of PBS, absorbed onto freshly prepared collodium-covered nickel grids, and then rinsed with distilled water. After being air-dried, the grids were treated with a 1:100 dilution of the cross-adsorbed serotype 2-specific antibody for 15 min at room temperature. Unbound antibody was removed by a mild spray of PBS from a plastic bottle. The bound antibodies were made visible for electron microscopic examination by incubating the grids on drops of protein A-gold complexes (10-nm gold particle size, with a concentration (A520) = 0.01) for 10 min at room temperature. The grids were subsequently rinsed with a mild spray of PBS containing 0.01% Tween 20 and then distilled water. After being air-dried the grids were unidirectionally metal shadowed with platinum. Samples (Fig. 1) . The distance between the promoter and the translational start site was taken into consideration in subsequent experiments designed to clone the native promoter and structural gene into the broad-host-range plasmid pDSK519 (9) as described below. For the recombinant serotype 2 fimbrial subunit expressed in E. coli, RNA was isolated from E. coli CAG629(pMW10) (28) after induction for 1 h at 42°C. Plasmid pMW10 contains a 0.8-kb fragment carrying the gene of the serotype 2-specific fimbrial subunit downstream of and in the same orientation as the lambda PL and PR promoters of the expression vector pJLA503 (25) . This plasmid was designed to express an intact fimbrial subunit protein with its original leader peptide. The subunit gene had previously been modified to reduce the RNA secondary structure between the atpE translational initiation region (TIR) of the vector and the NH2-terminal coding region so as to obtain efficient expression in E. coli (28) . The RNA start site was found to be located 173 nucleotides upstream of the ATG start codon. This is in agreement with the start site reported for the lambda PL promoter that is incorporated upstream of the ATG start codon in the vector pJLA503 (25) . There was no evidence of another start site further upstream correlating with the position of the lambda PR promoter present in pJLA503 (Fig. 1) . This is consistent with the finding that less than 5% of transcripts originate from the PR promoter in pJLA503 (16a).
Construction of expression plasmids. Broad-host-range plasmids were constructed to transfer the B. pertussis serotype 2-specific fimbrial subunit gene, under the control of native and E. coli expression signals, to B. parapertussis and B. bronchiseptica. The modified subunit gene and atpE TIR were subcloned from pMW10 into the broad-host-range vector pDSK519 in the same orientation as the PLAC promoter of the vector to produce pMW12. The modified gene, atpE TIR, and PL and PR promoters were also subcloned into pDSK519 in the opposite orientation to PLAC to produce pMW14. Plasmid pMW11 was identical to pMW12, except that the subunit gene encoding the methionylated mature form of the fimbrial subunit gene (i.e., lacking leader peptide) was cloned from pMW3 (28) into pDSK519. The wild-type B. pertussis serotype 2 fimbrial subunit promoter and structural gene was subcloned from plasmid pIL22 (15) into pDSK519 to form pMW17 (in the same orientation as PLAc) and pMW18 (in the opposite orientation) (Fig. 2) .
Expression of recombinant fimbrial protein in E. coli. Substantial amounts of the 25.0-kDa recombinant fimbrial subunit were detected in E. coli CAG629 (lon proteasedeficient, heat shock protein-deficient) bacteria containing consensus Shine-Dalgarno regions (SD) are underlined. The inverted-repeat region of the wild-type gene is underlined with inverted arrows. The DNA sequence of the upstream regions of the wild-type and recombinant genes were taken from those reported for pIL22 (15) pMW12 and pMW14 after IPTG or temperature induction, respectively, but not in the same host containing pDSK519, which lacks the fimbrial gene insert; pMW17, which contains the wild-type promoter and gene sequence (Fig. 3A) Recombinant B. parapertussis M/S180 containing pMW17 or pMW18 produced higher levels of fimbrial subunit than B. pertussis Tohama, presumably as a consequence of the higher copy number of the subunit gene in these strains (Fig.  3B) . In B. bronchiseptica 5376, the fimbrial subunit gene was expressed at increasing levels by recombinants containing pMW12, pMW18, and pMW17. The higher expression of subunit in pMW17 over that in pMW18 may arise from both PLAC and the native promoter working in tandem, which would increase transcriptional levels of fimbrial subunit gene in B. bronchiseptica pMW17. Expression of the subunit protein from pMW12 suggests that PLAC and the atpE TIR function in B. bronchiseptica but not in B. parapertussis. However, no gene expression was detected in recombinants containing pMW14, in which the fimbrial subunit gene is under the control of the lambda promoters (Fig. 3C) from proteolytic degradation of the recombinant product because of the lack of expression of appropriate fimbrial accessory genes in this strain. Similarly, methionylated mature fimbrial subunit was not detected in B. bronchiseptica 5376 containing pMWll (results not shown). The lack of expression of such protein may have resulted from proteolytic degradation of the fimbrial subunit in the cytoplasm of the host.
Immunological characterization of recombinant fimbriae expressed in BordeteUla spp. Serotype 2-specific agglutination of the recombinant Bordetella spp. described above demonstrated that the fimbrial accessory genes of both B. parapertussis and B. bronchiseptica recognize and assemble B. pertussis fimbrial subunit (Fig. 4) . Furthermore, the rapidity of agglutination paralleled the amount of fimbrial subunit expressed, as seen in Western blots (Fig. 3) . This result was confirmed in ELISA experiments (Fig. 4) . The Immunoelectron microscopic localization of serotype 2 fimbrial protein by using the protein A-gold procedure. Cells were adsorbed to collodium films, air-dried, and incubated with serotype 2 fimbrial antiserum that had been cross-adsorbed with B. pertussis H36, B. parapertussis M/S180, and B. bronchiseptica 5376 bacteria. The bound antibodies were visualized by incubation with protein A-gold complexes (10 nm) . Shown are B. pertussis Tohama (A); B. parapertussis M/S180 containing pDSK519 (B) and pMW17 (C); and B. bronchiseptica 5376 containing pDSK519 (D), pMW12 (E), and pMW17 (F). G, Gold particle; F, fimbriae. Bars, 0.25 p.m. type 2-specific fimbriae were produced, as represented by B. pertussis Tohama, B. parapertussis M/S180(pMW17), and B. bronchiseptica 5376 containing pMW12 or pMW17, the fimbriae were specifically labeled (Fig. 5A, C, E, and F) 2 subunit expression is least, the intensity of fimbrial immunolabeling was decreased compared with B. pertussis Tohama and B. bronchiseptica 5376(pMW17) fimbriae. This suggests that the fimbriae are of a mixed nature, containing both wild-type and recombinant fimbrial subunits. Fimbriae were not detected on every bacterium for all the strains tested which were taken from BG plates ( Fig. 5D and E) . It was found that vigorous resuspension of cells resulted in loss through shearing of almost all fimbriae and that gentle cell suspension was a critical step in fimbrial detection. However, fimbrial phase variation may also play a role in this process (30) . DISCUSSION It has been demonstrated that the serotype 2 fimbrial subunit protein is immunologically distinct from whole fimbriae (14) . In an earlier communication, we reported expression of the B. pertussis serotype 2 fimbrial subunit in E. coli. After purification and renaturation, the subunit assembled to form fimbriallike structures. However, although the recombinant subunit polymers and wild-type fimbriae were composed of the same protein subunit, they exhibit only limited cross-reactivity (28) . In this report we demonstrate that recombinant serotype 2 fimbrial subunit is produced in Bordetella spp. expressing fimbrial accessory genes as fimbriae that are indistinguishable from native fimbriae. As was previously shown for the pertussis toxin promoter (13), the serotype 2 fimbrial subunit promoter was found to function in both B. parapertussis and B. bronchiseptica. Although the regions upstream of both the pertussis toxin operon and the serotype 2 fimbrial subunit gene show some degree of homology (30) , the distances between the start sites of transcription and translation are very different, namely, 25 nucleotides in the case of the pertussis toxin Si subunit (19a) and 146 nucleotides in the case of the serotype 2 fimbrial subunit gene. Expression of fimbriae in B. pertussis is controlled by the bvg virulence regulatory locus and is subject to fimbrial phase variation. Recently, Willems et al. (30) reported that fimbrial phase variation may be due to insertion-deletion events within a C-rich region located some 57 nucleotides upstream of the ATG start site of the serotype 2 subunit gene. However, further investigation is required to determine whether or not other factors, including the inverted repeat region that overlaps the wild-type transcriptional start site (Fig. 1B) , are involved in the control of fimbrial expression.
In contrast to B. parapertussis, in which only the native B. pertussis promoter was functional, the heterologous expression signals PLAC and the atpE TIR functioned in B. bronchiseptica 5376 to express the fimbrial subunit. Although this construction was expected to function constitutively, the fimbrial subunit was not detected by Western blot analysis in nonfimbriated B. bronchiseptica ATCC 10580. The lack of fimbrial accessory gene expression as a result of the bvg mutant genotype of this strain may result in proteolytic degradation of the fimbrial subunit. Similarly, another construction designed to express the methionylated mature form of the fimbrial subunit did not produce detectable levels of subunit protein in B. bronchiseptica 5376. These experiments highlight the importance of fimbrial accessory genes and correct processing and transport of the fimbrial subunit to the periplasm: loss of either function results in a total absence of product accumulation. We are currently trying to isolate the B. pertussis fimbrial accessory genes, with the expectation that constitutive expression of such genes may facilitate the expression of B. pertussis fimbriae in B. bronchiseptica and E. coli strains.
For the preparation of a recombinant acellular whooping cough vaccine, purified antigens that are immunologically similar to the wild-type form must be produced. It has been shown that both recombinant pertussis toxin and serotype 2 fimbrial subunit are antigenically distinct when prepared from E. coli (3, 28) but that recombinant pertussis toxin subunits produced in B. parapertussis and B. bronchiseptica assemble as native holotoxin (13) . As shown here, recombinant serotype 2 fimbrial subunit is also produced as whole fimbriae in Bordetella spp. expressing fimbrial accessory genes. Such bacteria offer several advantages for antigen production over B. pertussis with regard to growth rates and requirements (13) . Furthermore, the fimbrial subunit was expressed in B. bronchiseptica under the control of PLAC and the atpE TIR. The constitutive expression of vaccine components in B. bronchiseptica may offer considerable advantages in terms of product yields.
